Document › Details
Bio-Rad Laboratories, Inc.. (3/23/09). "Press Release: Bio-Rad and Bruker Sign Joint Product Development and Co-marketing Agreement. Bio-Rad and Bruker Partner to Offer New Solutions for Biomarker Discovery and Development". Hercules, CA & Billerica, MA.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, and Bruker Corporation (NASDAQ: BRKR), a leading manufacturer of mass spectrometry (MS) instruments, today announced that they have signed an exclusive partnership agreement to develop and market new products based on Bio-Rad's surface-enhanced laser desorption/ionization (SELDI) technology in combination with Bruker's matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF/TOF) mass spectrometers for applications of high-throughput protein profiling and identification. The products will provide new solutions for biomarker discovery, in particular, the detection and high-confidence identification of intact peptides and proteins under 30 kilodaltons, which are known to be challenging for currently available technologies to identify.
"We're confident that Bio-Rad's SELDI technology combined with the flexibility delivered by Bruker's TOF/TOF systems will offer tangible benefits to researchers for protein biomarker discovery," said Brad Crutchfield, Bio-Rad Vice President and Life Science Group Manager. "We welcome the opportunity to work with Bruker, a company that, similar to Bio-Rad, has a long history of advancing life science research through its commitment to customer support."
"We are excited about working with Bio-Rad," said Dr. Gary Kruppa, Vice President for Business Development at Bruker Daltonics. "Bruker Daltonics' high-performance TOF/TOF technology will bring a new dimension to protein profiling and identification, expanding the capabilities of Bio Rad's established SELDI technology. New products based on this combination of technologies will allow access to new technical capabilities and new market segments in applied proteomics, enabling researchers to better identify and characterize new biomarkers."
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.
About Bruker Daltonics
Bruker Daltonics is a leading manufacturer of mass spectrometry (MS) instruments and accessories for life science, pharmaceutical, biochemical and chemical research as well as for applied analytical tasks in forensics and food safety. Technical solutions are based on a comprehensive range of MALDI-TOF/TOF, ESI-Qq-TOF, ESI-ITMS, and ESI/MALDI-FTMS mass spectrometry systems, as well as automated sample handling systems and productivity enhancing software. For more information about Bruker Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com and www.bruker.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Tina Cuccia, Corporate Communications Manager
Bio-Rad Laboratories, Inc.
Stacey Desrochers, Investor Relations
Phone: 978-663-3660 x 1115
Record changed: 2016-03-19
More documents for Bio-Rad (Group)
-  John Wiley & Sons. (11/30/16). "Press Release: Wiley Launches New Spectra Lab Applications to Help Scientists Manage Analytical Data"....
-  John Wiley & Sons. (7/26/16). "Press Release: Wiley Announces Launch of Wiley Spectra Lab, Giving Researchers Access to Largest Collection of Reference Spectra in the World"....
-  GE Healthcare. (8/13/11). "Press Release: GE Healthcare and Bio-Rad Reach Settlement in Label-free Detection Lawsuit". Chalfont St. Giles....
-  Bruker Corporation. (7/13/09). "Press Release: Bio-Rad Introduces the Lucid ID Access Pack to Complete Top-down Biomarker Discovery Workflow". Hercules, CA & Billerica, MA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to email@example.com and simply fill the subject line with the word »MSC newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]